Business Wire

Immunocore Appoints Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer

Jaa

Immunocore Limited, a leading T cell receptor (TCR) biotechnology company, today announces that Dr Mohammed Dar has been appointed as Head of Clinical Development and Chief Medical Officer, effective April 16, 2019.

Commenting on the appointment, Bahija Jallal Chief Executive Officer of Immunocore, said: “Immunocore is approaching a crucial point in the Company’s development, with our lead product candidate, tebentafusp, moving through pivotal studies. Mohammed has a complete breadth of experience in leading clinical teams through early and late stage development. We’re delighted to have such a distinguished physician, scientist and industry leader join us as we progress tebentafusp and our other promising candidates through clinical development.

Mohammed will be responsible for clinical, operational, biostatistics and medical affairs functions across all therapeutic areas. This includes Immunocore’s wholly-owned lead programme, tebentafusp, in addition to the growing pipeline in oncology, infectious diseases, which includes target indications such as Hepatitis B and HIV, and autoimmune diseases.

“The potential of Immunocore’s unparalleled science and TCR platform is very impressive,” said Mohammed Dar, Head of Clinical Development and Chief Medical Officer of Immunocore. “I am thrilled to have joined Immunocore at such an exciting time for the Company and I look forward to working with the scientific leadership team to drive this compelling science forward.”

Mohammed has over 15 years of pharmaceutical industry experience in the field of oncology. Before joining Immunocore, Mohammed was Vice President, Clinical Development Oncology, R&D at MedImmune (AstraZeneca) and spent 10 years at GSK in roles of increasing responsibility focused on early clinical development in oncology. While at MedImmune, he led the clinical trials and teams supporting the approval of anti-PD-L1 checkpoint inhibitor, durvalumab, and anti-CD22 immunotoxin, moxetumomab. Mohammed received his Bachelor’s Degree in Chemistry from the University of North Carolina at Chapel Hill and his M.D. and Internal Medicine training from Duke University School of Medicine. He went on to complete his Fellowship in Hematology and Oncology at the National Cancer Institute.

Mohammed joins two other world-class development leaders at Immunocore, Mark Moyer, Head of Regulatory, Safety and Project Management, and Koustubh Ranade, Head of Translational Medicine. Mark is one of the most experienced immuno-oncology development leaders with over 30 years of drug development experience at companies including Bristol-Myers Squibb (BMS) and Sanofi. As regulatory oncology head at BMS, he was accountable for 37 BLAs/MAAs, including for nivolumab, ipilimumab and elotuzumab. Koustubh was most recently Vice President of Translational Medicine at MedImmune for all therapeutic areas, where he contributed to four product approvals, including durvalumab. With over three decades of research experience at Genentech, BMS, Stanford and NIH, Koustubh is a co-inventor on many patents, has published extensively in top-tier journals and has edited a book on genomics.

About Immunocore

Immunocore, a leading T Cell Receptor (TCR) biotechnology company, is focused on delivering first-in-class

biological therapies that have the potential to transform the lives of people with serious diseases. The Company’s primary therapeutic focus is oncology and it also has programmes in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programmes in development and the lead programme, tebentafusp (IMCgp100), has entered pivotal clinical studies as a treatment for patients with metastatic uveal melanoma. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, UK, with offices in Conshohocken and Rockville, USA. The Company is privately held by a broad international investor base. For more information, please visit www.immunocore.com.

Contact information

Immunocore
Louise Conlon, External Affairs and Brand Communications Manager
T: +44 (0) 1235 438600
E: info@immunocore.com
Follow on Twitter: @Immunocore

Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/Jessica Hodgson/Chris Welsh/Melissa Gardiner
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

The Posiflex Group Showcases an Ecosystem of Connected Solution Endpoints with IoT Remote Monitoring at Computex 201924.5.2019 04:00:00 EESTTiedote

For the Computex 2019 show, The Posiflex Group is featuring leading solution technology from the family of brands as a fully Serviced IoT Ecosystem. Solution end points include: Connected Modular Kiosks, POS Terminals, and Digital Signage solutions from Posiflex and KIOSK Information Systems Smart Medical Displays with gesture controls from Portwell Connected Gaming Solutions with Player Tracking Technology from Portwell subsidiary, Ganlot The booth display is based on common field service endpoints represented in a European Manor Destination Resort setting. Field solutions for an array of vertical market applications include QSR ordering, cinema ticketing, fashion retail customer loyalty, interactive signage, hotel / medical center check-in and bill pay, as well as casino gaming technology. This year, in addition to their renowned POS product suite, Posiflex will be featuring newly introduced Modular Kiosk platforms (co-designed by KIOSK and Posiflex), which are configure-to-order sta

Audi China President Thomas Owsianski to Keynote at CES Asia 201923.5.2019 23:00:00 EESTTiedote

The Consumer Technology Association (CTA)TM today announced that Thomas Owsianski, president of Audi China, will deliver a keynote address at the upcoming CES Asia 2019. Now in its fifth year, CES Asia will run June 11-13, 2019 at the Shanghai New International Expo Centre (SNIEC) in Shanghai, China. Thomas Owsianski’s keynote is scheduled for 4 PM, Tuesday, June 11, where he will unveil Audi’s vision in transforming mobility from a driving experience to a digital adventure. Mr. Owsianski joined the top management team of Audi China in August 2018 and was named President in October 2018. “Audi has been at the forefront of driving global transformation in the automotive industry through their breakthrough advancements in technology,” said Karen Chupka, executive vice president, CES. “Innovation has revolutionized the transportation experience, and we welcome Mr. Owsianski to the CES Asia stage to share Audi’s vision for the future of global mobility.” Throughout Asia and beyond, technol

ITechLaw Publishes New Book and Opens Global Public Comment Period on Draft Principles for Responsible Artificial Intelligence23.5.2019 22:11:00 EESTTiedote

The International Technology Law Association (ITechLaw) has published Responsible AI: A Global Policy Framework, a new book that provides an in-depth review and eight discussion principles that address some of the hottest technology and moral issues of responsible development, deployment and use of artificial intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190523005752/en/ ITechLaw releases new book, Responsible AI: A Global Policy Framework, and opens public comment period. (Photo: Business Wire) Written by a multi-disciplinary group of 54 technology law experts, industry representatives and researchers from 16 countries, the book offers an actionable framework built on the following principles: Ethical Purpose and Societal Benefit, Accountability, Transparency and Explainability, Fairness and Non-discrimination, Safety and Reliability, Open Data and Fair Competition, Privacy, and AI and Intellectual Property.

Kumulus Vape, the 100% Online E-Cigarette Specialist, Goes Public23.5.2019 19:49:00 EESTTiedote

Kumulus Vape (ISIN FR0013419876 – MLVAP ), an online retailer specialised in the sale of electronic cigarettes and related products (devices, e-liquid and accessories), referred collectively as “e-cigarettes”, is pleased to announce the listing of its shares on the Euronext Access™ compartment in Paris by technical admission (Euronext notice PAR_20190523_05573_ACC). First listing will take place on 28 May 2019. This initial public offering - a first in Europe’s e-cigarette space - is a new milestone in the performance trajectory of the Lyon-based company, a pioneer on this market in acceleration phase. Kumulus Vape posted 2018 sales of €6.5 million, up 116% on 2017. Its outlook is highly auspicious, with 96% quarter-on-quarter growth in the first quarter of 2019. Kumulus Vape’s goal is clear: to become one of the French leaders in 100% online e-cigarette retail within three years. AN E-CIGARETTE PIONEER A CATALOGUE OF OVER 6,000 REFERENCES Kumulus Vape is one of the top online French r

Andersen Global Expands UK Locations23.5.2019 16:30:00 EESTTiedote

Claritas Tax Limited, a Birmingham, United Kingdom-based collaborating firm of Andersen Global, has opened a new office location in Deansgate, Manchester city center. This means that Andersen Global now has a presence in six locations in the UK through its member firms and collaborating firms. “Now more than ever, it’s important that businesses have easy access to quality advice in the UK’s dynamic political and business environment. The addition of another location in the region adds to our existing capabilities and will allow us to continue providing best-in-class service,” said Mark Vorsatz, Andersen Global Chairman and CEO of Andersen Tax LLC. Founded in 2012, Claritas Tax Limited has a list of clientele from entrepreneurial, privately owned, venture capital, and private equity owned businesses, listed companies and stakeholders. Claritas provides a broad range of tax consulting services, including all aspects of M&A and transactional taxes, R&D and Intellectual Property claims, sh

Mindbreeze Receives Attestation in Accordance with BSI Cloud Requirements23.5.2019 16:11:00 EESTTiedote

Mindbreeze receives attestation for its Mindbreeze InSpire SaaS service according to the specifications of the C5 catalogue of requirements (Cloud Computing Compliance Controls Catalogue, abbreviated C5), published by the German Federal Office for Information Security (BSI). The Mindbreeze InSpire SaaS service is professionally operated in Mindbreeze data centers on behalf of the customers. The attestation was issued by KPMG Alpen-Treuhand GmbH Wirtschaftsprüfungs- und Steuerberatungsgesellschaft. “The number of cloud services in the field of data analysis is growing steadily. This makes it all the more essential for customers to take a closer look at the choice of suppliers. C5 provides the regulatorily defined IT security level, which is comparable to the IT basic protection level that is increased by cloud controls,” explains Klaus Schatz, Managing Director of KPMG Advisory GmbH. C5 attestation (ISAE 3000 Report Type 2) is a recognized and authoritative verification for all customer

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme